Shares of Novo Nordisk plummeted by over 16% following disappointing results from clinical trials of its new weight-loss drug, CagriSema. The drug, which combines cagrilintide and semaglutide, was expected to demonstrate significant weight loss but fell short of expectations, achieving only 23% weight loss after 84 weeks, compared to 25.5% for Eli Lilly’s rival drug, Zepbound.

Why It Matters

This setback is significant for Novo Nordisk, which has seen its stock value drop by £350 billion, erasing gains made from the successful launch of its blockbuster drug, Wegovy. Analysts have described the trial results as a “swing and a miss,” raising concerns about the company’s ability to compete effectively in the rapidly growing weight-loss drug market.

What’s Next

Following these results, it remains uncertain whether Novo Nordisk will proceed with the market launch of CagriSema. The company faces an uphill battle against Eli Lilly, which has gained a competitive edge with Zepbound. Investors and analysts will be closely monitoring Novo’s next steps in response to this critical situation.

The post Novo Nordisk Faces Setback as CagriSema Declared Obsolete appeared first on DG News Sport.